Henry E Wiley1, Valerie Krivosic2,3, Alain Gaudric2,3, Michael B Gorin4, Carol Shields5, Jerry Shields5, Mary E Aronow6, Emily Y Chew1. 1. National Eye Institute, National Institutes of Health, Bethesda, Maryland. 2. Service d'Opthalmologie, APHP, Hôpital Lariboisière, Université Paris-Diderot, Sorbonne Paris Cité. France. 3. Centre de Référence des Maladies Vasculaires Rares du Cerveau et de l'OEil (CERVCO), Hôpital Lariboisière, APHP, Paris, France. 4. Jules Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. 5. Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. 6. Ocular Oncology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts.
Abstract
PURPOSE: To review the current state of diagnosis and management of retinal hemangioblastoma and retinal vascular proliferation arising from von Hippel-Lindau (VHL) disease. METHODS: A review of the literature was performed. Consensus was reached among authors regarding current practice, with reference to published data where possible. RESULTS: von Hippel-Lindau disease and its ocular manifestations are relatively rare, and there is limited evidence in the literature on which to base management. There was consensus on core principles, including 1) recognition and diagnosis of von Hippel-Lindau disease when present, with appropriate referral for care of this potentially lethal systemic condition; 2) regular ophthalmic evaluation for individuals with von Hippel-Lindau disease, to identify and offer timely treatment for new or active retinal hemangioblastomas; 3) ablative treatment of retinal hemangioblastomas that can be safely destroyed, to lower risk of vision loss; 4) observation or consideration of nonablative treatments for retinal hemangioblastomas that cannot be safely destroyed; and 5) observation of asymptomatic retinal vascular proliferation, with consideration of vitrectomy for lesions exerting effects on vision. CONCLUSION: Ocular outcomes can be gratifying in many cases with appropriate management. Improved understanding of the molecular basis for the disease creates an opportunity for rational design of better therapies.
PURPOSE: To review the current state of diagnosis and management of retinal hemangioblastoma and retinal vascular proliferation arising from von Hippel-Lindau (VHL) disease. METHODS: A review of the literature was performed. Consensus was reached among authors regarding current practice, with reference to published data where possible. RESULTS:von Hippel-Lindau disease and its ocular manifestations are relatively rare, and there is limited evidence in the literature on which to base management. There was consensus on core principles, including 1) recognition and diagnosis of von Hippel-Lindau disease when present, with appropriate referral for care of this potentially lethal systemic condition; 2) regular ophthalmic evaluation for individuals with von Hippel-Lindau disease, to identify and offer timely treatment for new or active retinal hemangioblastomas; 3) ablative treatment of retinal hemangioblastomas that can be safely destroyed, to lower risk of vision loss; 4) observation or consideration of nonablative treatments for retinal hemangioblastomas that cannot be safely destroyed; and 5) observation of asymptomatic retinal vascular proliferation, with consideration of vitrectomy for lesions exerting effects on vision. CONCLUSION: Ocular outcomes can be gratifying in many cases with appropriate management. Improved understanding of the molecular basis for the disease creates an opportunity for rational design of better therapies.
Authors: P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe Journal: Nature Date: 1999-05-20 Impact factor: 49.962
Authors: Xuejing Chen; Christian J Sanfilippo; Aaron Nagiel; Hamid Hosseini; Devery Mitchell; Colin A McCannel; Steven D Schwartz; Tara A McCannel Journal: Retina Date: 2018-04 Impact factor: 4.256
Authors: Reecha Sachdeva; Hajir Dadgostar; Peter K Kaiser; Jonathan E Sears; Arun D Singh Journal: Acta Ophthalmol Date: 2010-10-14 Impact factor: 3.761
Authors: F Latif; K Tory; J Gnarra; M Yao; F M Duh; M L Orcutt; T Stackhouse; I Kuzmin; W Modi; L Geil Journal: Science Date: 1993-05-28 Impact factor: 47.728
Authors: E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton Journal: J Med Genet Date: 1991-07 Impact factor: 6.318
Authors: Reinier Alvarez; Panagiotis Mastorakos; Elizabeth Hogan; Gretchen Scott; Russell R Lonser; Henry E Wiley; Emily Y Chew; Prashant Chittiboina Journal: Neurosurgery Date: 2021-04-15 Impact factor: 4.654